Use of milbemycin oxime in the treatment of dogs with nasal mite (Pneumonyssoides caninum) infection.
Clinical diagnosis of canine nasal mite (Pneumonyssoides caninum) infection is difficult due to the mite's location in the caudal nasal cavity and frontal sinuses. The current study was performed to evaluate the efficacy of milbemycin oxime in treating dogs with nasal mite infection. A prospective open uncontrolled study included 20 dogs with case histories indicating possible nasal mite infection. Inclusion criteria consisted of either nasal mites being demonstrated (group 1, four dogs), or suspicious clinical signs with no other apparent causes, combined with eosinophilia (group 2, 16 dogs). Milbemycin oxime 1 mg/kg was given orally three times at 10-day intervals. In 17 (85 per cent) dogs, clinical signs resolved completely following milbemycin therapy; within 10 days of the first treatment in 13 cases (group 1, four dogs; group 2, nine dogs) and within 14 days in four cases. In the remaining three dogs clinical signs persisted but were diminished.
Bredal
W
W
Norwegian College of Veterinary Medicine, Department of Small Animal Clinical Sciences, Oslo, Norway.
Vollset
I
I
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D018942:Macrolides; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D009296:Nasal Cavity
D000900:Anti-Bacterial Agents; D000977:Antiparasitic Agents; D018942:Macrolides; C078973:milbemycin oxime